The link we observed between polymorphisms in HDAC3 and CTLA4 expression is supported by the study in which HDAC inhibitor Belinostat was found to potentiate the antitumor effect of anti-CTLA4 antibody in subcutaneous murine model of HCC [51]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.